Cenicriviroc
| Title | Journal |
|---|---|
| A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. | Hepatology (Baltimore, Md.) 20180501 |
| Chemokine receptor antagonists. | Journal of medicinal chemistry 20121126 |
| Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. | Journal of medicinal chemistry 20110609 |
| The relative activity of 'function sparing' HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? | Molecular pharmacology 20090301 |
| Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. | Antimicrobial agents and chemotherapy 20070201 |
| Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. | Journal of medicinal chemistry 20060323 |
| TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. | Antimicrobial agents and chemotherapy 20051101 |
| Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. | Journal of medicinal chemistry 20050127 |